XML 36 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2018
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model

The fair value of the Series 1 preferred stock was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events.    If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following:

 

Risk-free interest rate

     1.04

Expected dividend rate

     0  

Expected volatility

     70.50

Preferred stock conversion limit - percentage of outstanding common stock

     19.90

Preferred conversion floor price

   $ 1.00  
Fair Values of Derivative Instruments to be classified as Derivative Liabilities on Balance Sheet

Fair values of derivative instruments to be classified as derivative liabilities on the balance sheet consist of the following:

 

($ in thousands)              

Liability derivates:

   Balance Sheet Location      Fair Value  

September 30, 2018:

     

Derivative liabilities

     Liabilities      $ 2,597  
     

 

 

 
Change in Derivative Liability

The change in the derivative liability for the nine months ended September 30, 2018 consisted of the following:

 

($ in thousands)       
     Fair Value  

Balance, December 31, 2017

   $                 2,424  

Dividends

     73  

Change in fair value

     (28
  

 

 

 

Balance, March 31, 2018

   $ 2,469  
  

 

 

 

Dividends

     72  

Change in fair value

     (183
  

 

 

 

Balance, June 30, 2018

   $ 2,358  
  

 

 

 

Dividends

     74  

Change in fair value

     165  
  

 

 

 

Balance, September 30, 2018

   $ 2,597  
  

 

 

 
Series 1 Preferred Stock  
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model

The fair value of the Series 1 preferred stock dividends was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events.    If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following:

 

     September 30, 2018     December 31, 2017  

Risk-free interest rate

     2.97     1.92 - 2.12

Expected dividend rate

     0       0  

Expected volatility

     77.60     68.7 - 80.4

Preferred stock conversion limit - percentage of outstanding common stock

     19.90     19.90

Preferred conversion floor price

   $ 1.00     $ 1.00